Functional Consequences of the Somatopause and its Treatment

Andrew R. Hoffman; Steven A. Lieberman; Gail Butterfield; Janice Thompson; Raymond L. Hintz; Gian Paolo Ceda; Robert Marcus

doi:10.1007/bf02778067

Functional Consequences of the Somatopause and its Treatment

Andrew R. Hoffman, Steven A. Lieberman, Gail Butterfield, Janice Thompson, Raymond L. Hintz, Gian Paolo Ceda, Robert Marcus

Internal Medicine

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

The decline in the function of the growth hormone-releasing hormone, growth hormone, insulin-like growth factor (GHRH-GH-IGF) axis has been termed the somatopause. Many of the catabolic sequelae seen in normal aging has been attributed to this decrease in circulating GH and IGF-I. In order to provide hormone replacement therapy for the somatopause, elderly subjects have been treated with GH, IGF-I, or both hormones together. Whereas numerous beneficial effects on body composition, strength, and quality of life have been reported in some studies, other studies have reported only marginal functional improvements. Moreover, it is clear that both hormones can cause significant morbidity.

Original language	English (US)
Pages (from-to)	73-76
Number of pages	4
Journal	Endocrine
Volume	7
Issue number	1
DOIs	https://doi.org/10.1007/bf02778067
State	Published - 1997

Keywords

Body composition
GH
IGF-I
Somatopause

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology

Access to Document

10.1007/bf02778067

Cite this

@article{a27df97930344764aee556309d02018a,

title = "Functional Consequences of the Somatopause and its Treatment",

abstract = "The decline in the function of the growth hormone-releasing hormone, growth hormone, insulin-like growth factor (GHRH-GH-IGF) axis has been termed the somatopause. Many of the catabolic sequelae seen in normal aging has been attributed to this decrease in circulating GH and IGF-I. In order to provide hormone replacement therapy for the somatopause, elderly subjects have been treated with GH, IGF-I, or both hormones together. Whereas numerous beneficial effects on body composition, strength, and quality of life have been reported in some studies, other studies have reported only marginal functional improvements. Moreover, it is clear that both hormones can cause significant morbidity.",

keywords = "Body composition, GH, IGF-I, Somatopause",

author = "Hoffman, {Andrew R.} and Lieberman, {Steven A.} and Gail Butterfield and Janice Thompson and Hintz, {Raymond L.} and Ceda, {Gian Paolo} and Robert Marcus",

note = "Funding Information: Supported by NIH grant AG 10999, and the Reserarch Service of the Department of Veterans Affairs.",

year = "1997",

doi = "10.1007/bf02778067",

language = "English (US)",

volume = "7",

pages = "73--76",

journal = "Endocrine",

issn = "0969-711X",

publisher = "Humana Press",

number = "1",

}

TY - JOUR

T1 - Functional Consequences of the Somatopause and its Treatment

AU - Hoffman, Andrew R.

AU - Lieberman, Steven A.

AU - Butterfield, Gail

AU - Thompson, Janice

AU - Hintz, Raymond L.

AU - Ceda, Gian Paolo

AU - Marcus, Robert

N1 - Funding Information: Supported by NIH grant AG 10999, and the Reserarch Service of the Department of Veterans Affairs.

PY - 1997

Y1 - 1997

N2 - The decline in the function of the growth hormone-releasing hormone, growth hormone, insulin-like growth factor (GHRH-GH-IGF) axis has been termed the somatopause. Many of the catabolic sequelae seen in normal aging has been attributed to this decrease in circulating GH and IGF-I. In order to provide hormone replacement therapy for the somatopause, elderly subjects have been treated with GH, IGF-I, or both hormones together. Whereas numerous beneficial effects on body composition, strength, and quality of life have been reported in some studies, other studies have reported only marginal functional improvements. Moreover, it is clear that both hormones can cause significant morbidity.

AB - The decline in the function of the growth hormone-releasing hormone, growth hormone, insulin-like growth factor (GHRH-GH-IGF) axis has been termed the somatopause. Many of the catabolic sequelae seen in normal aging has been attributed to this decrease in circulating GH and IGF-I. In order to provide hormone replacement therapy for the somatopause, elderly subjects have been treated with GH, IGF-I, or both hormones together. Whereas numerous beneficial effects on body composition, strength, and quality of life have been reported in some studies, other studies have reported only marginal functional improvements. Moreover, it is clear that both hormones can cause significant morbidity.

KW - Body composition

KW - GH

KW - IGF-I

KW - Somatopause

UR - http://www.scopus.com/inward/record.url?scp=0031196695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031196695&partnerID=8YFLogxK

U2 - 10.1007/bf02778067

DO - 10.1007/bf02778067

M3 - Article

C2 - 9449036

AN - SCOPUS:0031196695

VL - 7

SP - 73

EP - 76

JO - Endocrine

JF - Endocrine

SN - 0969-711X

IS - 1

ER -

Functional Consequences of the Somatopause and its Treatment

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this